Tariquidar methanesulfonate hydrate

Research use only, not for human use.

A potent, specific P-gp inhibitor with Kd of 5.1 nM.

A potent, specific P-gp inhibitor with Kd of 5.1 nM; potentiates the cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine in a panel of human MDR cell lines at 25-80 nM; exhibits potent i.v. and p.o. activity without apparently enhancing the plasma pharmacokinetics of paclitaxel or the toxicity of coadministered drugs.Breast Cancer Phase 2 Discontinued

XR 9576;XR-9576;XR9576

Membrane Transporter/Ion Channel

P-glycoprotein

P-glycoprotein

Cancer

Breast Cancer

625375-83-9

892.99

C40H52N4O15S2

>98% (HPLC)

DMSO: ≥ 296 mg/mL; H2O: < 8.9 mg/mL

COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC.CS(=O)(=O)O.CS(=O)(=O)O.O.O.O

3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-, methanesulfonate, hydrate (1:2:3)

(-20℃)

With Ice Pack

≥ 2 years